CERo Therapeutics Holdings, Inc. (CERO) Dividend History

CERo Therapeutics Holdings, Inc. is a biopharmaceutical company focused on developing innovative cell therapies for cancer treatment. The company aims to enhance the immune system's ability to target and eliminate tumor cells through its proprietary technologies and therapeutic platforms.

201 Haskins Way, South San Francisco, CA, 94080
Phone: 650-407-2376
Website:

Dividend History

CERo Therapeutics Holdings, Inc. currently does not pay dividends

Company News

  • CERo Therapeutics Holdings, Inc. (CERO) has appointed Chris Ehrlich as its new CEO. The company is advancing the development of next-generation engineered T cell therapeutics for cancer treatment, with plans to initiate clinical trials for its lead product candidate CER-1236 in early 2025 for acute myeloid leukemia (AML).

    GlobeNewswire Inc.
  • Company anticipates near term filing of Investigational New Drug Application to FDA

    GlobeNewswire Inc.
  • SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides shareholders with a corporate update reviewing activities since its entering the public market.

    GlobeNewswire Inc.
  • Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share. Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares jumped 430% to $25.35 after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million. Xilio Therapeutics, Inc. (NASDAQ: XLO) gained 146% to $1.58 after the company announced an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program. The company announced a $11.3 million private placement equity financing. Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) shares climbed 80% to $1.5395. Biodexa's MTX110 showed promise in extending life expectancy against aggressive brain cancers. Ontrak, Inc. (NASDAQ: OTRK) gained 55% to $0.9239. Binah Capital Group, Inc. (NASDAQ: BCG) gained 48% to $14.05 after dipping more than 20% on Wednesday. Kidpik Corp. (NASDAQ: PIK) gained 40.7% to $4.5999. Kidpik recently regained compliance with the Nasdaq minimum bid price requirement. Allego N.V. (NASDAQ: ALLG) rose 32.8% to $1.7650. Akanda Corp. (NASDAQ: AKAN) gained 28% to $0.2053 after the company announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry. Destiny Tech100 Inc. (NASDAQ: DXYZ) rose 26% to $22.15. REX American Resources Corporation (NYSE: REX) gained 23.2% to $54.15 following upbeat earnings. Nutriband Inc. (NASDAQ: NTRB) gained 23% to $4.98. Nutriband recently provided a clinical and regulatory path overview for its AVERSA Fentanyl patch. Summit Therapeutics Inc. (NASDAQ: ...

    Benzinga
  • Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results. The company reported fiscal year 2023 losses of 96 cents per share, compared to losses of $3.78 per share from the prior year. Taysha reported it had $143.9 million in cash and cash equivalents on Dec. 31, 2023. The company also provided clinical updates including the completed dosing in cohort one of its REVEAL Phase 1/2 adolescent and adult trial and the expansion of the ongoing trial in Canada into the U.S. and initiated site activation. Taysha Gene Therapies shares jumped 27.1% to $2.86 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers ETAO International Co., Ltd. (NASDAQ: ETAO) shares rose 200.4% to $0.4296 in pre-market trading. The company announced a reverse stock split. Oblong, Inc. (NASDAQ: OBLG) rose 48.2% to $0.20 in pre-market trading after the company reported financial results for fourth quarter 2023 and issued a business update. BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) climbed 44% to $0.0288 in pre-market trading after falling 15% on Tuesday. ...

    Benzinga
Dividend data last updated 06/07/2025 15:38:29 UTC